Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer |
| |
Authors: | Todd W. Bauer MD Francis R. Spitz MD Linda S. Callans MD Abass Alavi MD Rosemarie Mick MS Susan P. Weinstein MD Isabelle Bedrosian MD Douglas L. Fraker MD Thomas L. Bauer MD Brian J. Czerniecki MD PhD |
| |
Affiliation: | (1) Department of Surgery, University of Pennsylvania, 3400 Spruce St., Pennsylvania;(2) Department of Nuclear Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;(3) Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania;(4) Department of Biostatistics and Epidemiology School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;(5) Department of Surgery, York Hospital, York, Pennsylvania;(6) Department of Surgery, 4 Silverstein, Hospital of the University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104 |
| |
Abstract: | Background Sentinel lymph node (SLN) mapping with radioisotope and blue dye is rapidly becoming the standard of care for breast cancer. The optimal location for injection of radioisotope and blue dye is still being investigated. The goal of this study was to determine whether blue dye injection into the subareolar (SA) location localized the same sentinel nodes as the peritumoral (PT) location for patients with breast cancer. Methods Three hundred thirty-two patients with biopsy-proven operable breast cancer or ductal carcinoma in situ at two institutions underwent SLN mapping. Eighty-three patients had PT injection of blue dye (group 1), and 249 patients had SA injection of blue dye (group 2). All patients underwent PT injection of99mTc-labeled sulfur colloid. Results The two groups were similar in age, previous biopsy type, and tumor size, location, and histology. The mean number of SLNs identified was 2.4 (range, 0–9) in group 1 and 2.5 (range, 0–11) in group 2. The SLN identification rate was 95% for group 1 and 97% for group 2. The isotope success rate was 94% for both groups. The blue dye success rate was 84% for group 1 and 90% for group 2. The isotope/blue dye concordance rate was 87% for group 1 and 90% for group 2. At a median follow-up of 28 months (range, 14 to 40), there were no axillary recurrences in any of the 332 patients. Conclusions These data suggest that delivery of mapping reagents in the SA and PT locations identifies similar lymph nodes. Because of simplicity and the similarity in node identification between SA and PT injection, further investigation of the SA site for delivery of SLN mapping reagents for breast cancer is warranted. Presented at the 54th Annual Cancer Symposium, Society of Surgical Oncology. Washington, DC, March 15–18, 2001. |
| |
Keywords: | Sentinel lymph node mapping Subareolar injection Blue dye Radioisotope Breast cancer |
本文献已被 PubMed SpringerLink 等数据库收录! |
|